Bayer sues Lupin over generic birth control pill
FRANKFURT (Reuters) - German drugmaker Bayer (BAYGn.DE) has filed a lawsuit in the United States against Indian generic drug maker Lupin (LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia in the U.S.
In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sales of the generic product.
Lupin declined to comment on the lawsuit. "We do not comment on on-going litigations as a matter of policy," said Lupin spokesperson Shamsher Gorawara.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware. (Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle; editing by Carol Bishopric)
- Tweet this
- Share this
- Digg this
- UPDATE 2-U.S. House passes bill to avert govt shutdown, extend Export-Import bank
- IPhone emerges from "bygone era", reviewers hail bigger handset
- UPDATE 1-Apple to unveil new iPads, operating system on Oct. 21 - report
- Fed renews zero rate pledge, but hints at steeper rate hike path
- UPDATE 2-Bug delays Apple's HealthKit availability on iOS 8
The United States said on Wednesday it will press Prime Minister Narendra Modi to end his blockage of a global trade pact when he visits Washington this month, something that could dampen the mood of a trip aimed at revitalizing strategic ties. Full Article
China cenbank injects $81 bln into major banks to support economy - reports Full Article